Cart is empty A breakthrough in the understanding of the relationship between a naturally occurring enzyme and the liver cancer drug sorafenib could improve the effectiveness of the drug, which currently prolongs the life of liver cancer patients for only two to three months. A study of the relationship between the enzyme DDX5, liver cancer sorafenib, published in the journal Cell Death & Disease, points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Leave A Comment